Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch® capsules 2.5 μg) in 3,762 hemodialysis patients with intractable pruritus.

BACKGROUND: Intractable pruritus in hemodialysis patients can significantly decrease their quality of life and is also associated with poor vital prognosis. Although combined multiple causes of intractable pruritus in these patients have been identified, no existing treatments are proven to be sufficiently effective. We conducted a post-marketing surveillance to follow-up and assess the safety and efficacy of nalfurafine, a selective κ-opioid receptor agonist, for the treatment of intractable pruritus in patients undergoing hemodialysis. PATIENTS AND METHODS: Hemodialysis patients with intractable pruritus from institutions in Japan who received oral nalfurafine hydrochloride between January 2010 and December 2013 were enrolled in the surveillance. Surveillance was completed in July 2015. Safety data during 1 year after nalfurafine treatment onset, and efficacy data of nalfurafine evaluating the first 12-week treatment period and the following period until 1 year after the initial dose of nalfurafine (using global assessment of the itch improvement by the physician, Visual Analog Scale, and the Shiratori's severity scores) were collected and analyzed.
RESULTS: In total, 3,762 patients were analyzed for safety. Adverse drug reactions were experienced by 402/3,762 (10.69%) patients. The most frequent adverse drug reactions were insomnia (127/3,762 [3.38%] patients), constipation (34 [0.90%]), somnolence (32 [0.85%]), dizziness (23 [0.61%]), nausea (13 [0.35%]), and malaise (9 [0.24%]). No patients developed dependence on nalfurafine. Nalfurafine was effective in 82.50% (2,880/3,491) of patients during the first 12 weeks and in 84.95% (2,167/2,551) on treatment during the subsequent period until 1 year after nalfurafine treatment initiation. Statistically significant decreases were reported in the Visual Analog Scale and the Shiratori's severity scores (p<0.001).
CONCLUSION: Oral nalfurafine hydrochloride (from 2.5 μg/day to a maximum of 5.0 μg/day) continues to be safe and effective for the treatment of intractable pruritus in hemodialysis patients in real-world clinical settings.

Background

As of December 2015, 324,986 patients in Japan were reportedly undergoing chronic hemodialysis.1 The number of hemodialysis patients is steadily increasing, partly due to the aging population and the growing number of patients with diseases such as diabetic nephropathy.2 Dialysis technology and treatment for complications have progressed in recent years, but the complications that decrease the quality of life of patients are still present and remain an urgent unmet clinical need.

Moderate to extreme pruritus is experienced by 42% of patients undergoing hemodialysis.3 As well as significantly impacting patients’ quality of life, intractable pruritus can also result in poor prognosis.3–6 None of the current treatment options for intractable pruritus in patients with hemodialysis, which include oral antihistamines and antiallergic agents, moisturizing agents or steroids, specifically selected dialysis membranes, type B ultraviolet light (ultraviolet B) therapy, or performing hemodiafiltration, are sufficiently effective.6–9 The same is also the case for treatments that are available internationally, such as gabapentin, pregabalin, mast cell stabilizers, cholestyramine, naltrexone, or thalidomide.10–13

Several complex factors contribute to the pathogenesis of intractable pruritus, including extended nerve fibers in the epidermis, chemical mediators, and endogenous opioids.14–19 Nalfurafine hydrochloride (Remitch capsules 2.5 μg; Toray Industries, Inc., Tokyo, Japan) is a selective κ-receptor agonist that was developed in 1992. In nonclinical studies, nalfurafine suppressed scratching behavior,20,21 showed no drug dependence (unlike morphine, which agonizes the μ-receptor),21–24 and, unlike the existing κ-receptor agonists, caused no aversion.25 As such, it was considered to be a promising agent for the treatment of intractable pruritus in hemodialysis patients. Clinical trials were, therefore, conducted with nalfurafine with the aim of developing a novel anti-itch agent.

The efficacy of nalfurafine for this condition was first demonstrated in the confirmatory trial, a 14-day, multicenter, double-blind, placebo-controlled trial, in which 337 Japanese hemodialysis patients with intractable pruritus resistant to existing treatment were randomly treated with either nalfurafine (2.5 or 5.0 μg) or placebo per day.26 Nalfurafine was also demonstrated to be clinically effective in an open-label trial when administered at 5.0 μg/day for 1 year to 211 hemodialysis patients with intractable pruritus resistant to existing treatment.27 The latter long-term study found no psychological or physical dependence on nalfurafine.

Based on these results, nalfurafine was approved in Japan in 2009 for the treatment of pruritus in hemodialysis patients (for use only when sufficient efficacy is not obtained with existing therapies or treatments) and subsequently approved in Korea in 2013. A limitation of the above clinical trials was the relatively similar background of the registered patient populations. As such, we decided to conduct a post-marketing study (PMS) whose objectives were to reexamine the risks identified in the preceding trials, find hidden serious risks and missing key information, and enhance the adequate use of the agent while minimizing its risks.

Patients and methods

This surveillance was conducted in compliance with the Good Post-marketing Study Practice, or the Standard for Conducting Post-marketing Surveillance and Trials of Drugs, which is an ordinance enacted under the Japanese Pharmaceutical Affairs Law. This surveillance did not need informed consent from patients because it is not required under Japanese regulations.

Patients

Hemodialysis patients with intractable pruritus identified as receiving oral nalfurafine at any period between January 2010 and December 2013 were enrolled in the surveillance. Patients were administered nalfurafine after itch treatment with their existing therapy (ie, itch treatment approved in Japan, such as antihistamine/antiallergic agent, moisturizing agent, topical antihistamine, topical steroid, and ultraviolet B light therapy) was thought to be insufficiently effective by the physician. Surveillance was completed in July 2015. We planned to study 3,000 hemodialysis patients with intractable pruritus. The sample size was determined to enable detection of significance at the 95% CI of at least one case of a 0.1% frequency adverse drug reaction (ADR).

Design

Patients were registered at an independent patient registration center in this prospective surveillance with a 1-year observation period. Survey items included baseline patient characteristics, nalfurafine dosage regimen, hemodialysis plans, previous and concomitant treatment for pruritus, concomitant treatment for diseases other than pruritus, improvement in itch severity, laboratory test results (serum prolactin and thyroid hormones [thyroid-stimulating hormone {TSH}, free triiodothyronine, and free thyroxine] among others), dependence, and adverse events. Adverse events whose causation by nalfurafine cannot be denied were defined as ADRs.

As nonclinical studies and clinical trials had previously noted, nalfurafine induced variation of prolactin and TSH; therefore, measurements of these hormones were included in the laboratory test of this surveillance for further examination.

Also, in the preceding clinical trials, insomnia and somnolence were found in high frequency and hypomania was experienced as a psychiatric disorder; therefore, we further studied them in this surveillance.

It should be noted that the coadministration of nalfurafine with hypnotic, antianxiety, antidepressant, antipsychotic, or antiepilepsy drugs should be conducted using caution as it may enhance ADRs that affect the central nervous system. Frequencies of psychiatric and nervous system disorders were studied in this regard among the patients who received concomitant treatment using these drugs (excluding treatment drugs against adverse events).

Assessment of itch improvement

Improvement in itch severity was measured by three criteria: global assessment of the itch improvement by the physician’s diagnosis and observations from three phases (improved, stable, or aggravated), the Visual Analog Scale (VAS), and the Shiratori’s severity score.

The analysis of the global assessment of the itch improvement included only those patients whose status was considered to have “improved”, “stable”, or “aggravated”.

The VAS is an established technique used to assess a patient’s level of itch.28 The left end of a 100 mm horizontal line is labeled “no itch”, and the right end is labeled “itch as bad as it could be”. The patient marks on the line the point that most represents their itching sensation. Only those patients who had recorded their VAS values after breakfast and after evening meal, both prior to and after nalfurafine administration, were analyzed. Of the two values available, the larger VAS value was used in the analysis.

In the Shiratori’s severity score, which provided the basis for Kawashima’s classification scheme, the intensities of daytime and nighttime itching were reported using a 5-level scale.29,30 The benchmark descriptors for each level were as follows: 0 (ie, no symptoms) “daytime: no or almost no itch, nighttime: no or almost no itch”; 1 (ie, very slight) “daytime: occasional restless sensations that do not necessarily induce scratching behavior, nighttime: very little itch at bedtime that does not induce conscious scratching behavior and never disturbs sound sleep”; 2 (ie, slight) “daytime: itch that can be subdued by occasional reaching out and light scratching, nighttime: occasional itch that can be subdued by scratching and does not wake the patient”; 3 (ie, moderate) “daytime: significant scratching even in public or irritating itch causes ceaseless scratching, nighttime: the itch disrupts sleep, and although the patient can go back into sleep after scratching, the patient keeps scratching unconsciously”; and 4 (ie, fierce) “daytime: unbearable itch causes scratching and scratching only aggravates the itch sensation and interferes with work or study, nighttime: almost deprived of sleep, the patient keeps scratching ceaselessly, which only aggravates the itch sensation”. The analysis of the Shiratori’s severity score included only those patients who recorded daytime and nighttime scores both prior to and after nalfurafine administration; the larger value of the two scores was used for the analysis.

The assessments were made according to the following schedule: the global assessment of the itch improvement was checked at 12 weeks (or upon treatment interruption, if applicable) and at 1 year (or upon treatment interruption, if applicable) after the initial dose of nalfurafine. The VAS value and the Shiratori’s severity score were checked within 30 days before nalfurafine initiation. After the initial dose of nalfurafine, the VAS values and Shiratori’s severity scores were recorded at 12 weeks (or upon treatment interruption, if applicable) and at 1 year (or upon treatment interruption, if applicable).

Assessment of dependence

Dependence was evaluated with the Questionnaire of Drug Dependence comprising psychological dependence-related questions, physical dependence-related questions, and tolerance related questions for the periods up to 12 weeks and between 13 weeks and 1 year.27,31 For each period, dependence during nalfurafine treatment was measured by 10 questions. Additionally, in case treatment was interrupted during each observation period, dependence during the 4 weeks after the end of treatment was assessed by six questions. Each patient was assigned one of four options (“remarkable”, “moderate”, “slight”, or “none”). If a patient’s symptoms were described as either “remarkable” or “moderate”, the reasons expressed by the patient and the findings of the physician were also recorded for further consideration.

Statistical analysis

The global assessment of the itch improvement was calculated as the point estimate of the improvement rate. The incidences of ADRs were counted in accordance with the MedDRA/J (version 18.1) preferred terms. Fundamental statistics were calculated from the VAS values, Shiratori’s severity scores, and the levels of serum prolactin and thyroid hormones observed in each patient. They were examined by the one-sample t-test for the difference between the pre- and posttreatment values, with two-sided p-values <0.05 considered as statistically significant. SAS version 9.1.3 software (SAS Institute Inc., Cary, NC, USA) was used for the statistical analyses.

Ethics approval and consent to participate

In accordance with the Japanese Ministry of Health, Labor, and Welfare, this surveillance was conducted in compliance with the Good Post-marketing Study Practice and the Standard for Conducting Post-marketing Surveillance and Trials of Drugs, which is an ordinance enacted under Article 14, Section 4, Clause 4 and Article 14, Section 6, Clause 4 of the Japanese Law (ie, Pharmaceuticals and Medical Devices Law) for Ensuring the Quality, Efficacy, and Safety of Drugs and Medical Devices. Separate ethics approval for this surveillance and informed consent to participate in the surveillance were not required under Japanese law. It should also be noted that all original data have been completely anonymized such that the privacy of patients or facilities involved was ensured.

Results

Baseline patient characteristics

A total of 3,866 patients were enrolled at 1,023 institutions; 3,762 patients were analyzed for safety of nalfurafine (Figure 1). Excluding 2 patients who had not undergone hemodialysis at the time, a total of 3,760 patients were analyzed for efficacy. Tables 1 and 2 show the major demographic characteristics and the treatment profile of the safety analysis set, respectively. In this surveillance, compared to the proportion of all hemodialysis patients in Japan,1 the ratio of males was slightly higher at 71.00% (2,671/3,762 patients). More males were registered than females, but almost no bias in sex or age was noted among the registered patients. In this surveillance, on the basis of the mean daily dose, 87.37% (3,287/3,762 patients) were administered nalfurafine at 2.5 μg, 11.59% (436/3,762 patients) received over 2.5 μg but <5.0 μg, and 0.74% (28/3,762 patients) received 5.0 μg (Table 2). While most of the registered patients kept taking the regular mean daily dose of 2.5 μg, at least 10% of patients received the elevated dose of 5.0 μg.

Figure 1

Participant flow diagram.

Abbreviations: CRF, case report form; VAS, Visual Analog Scale.

Table 1

Baseline demography and disease characteristics

Baseline patient characteristics	Patients (n)	Ratio (%)
Sex
Male	2,671	71.00
Female	1,091	29.00
Unknown or not recorded	0	0.00
Age (years)
0–19	0	0.00
20–29	10	0.27
30–39	70	1.86
40–49	231	6.14
50–59	501	13.32
60–69	1,103	29.32
70–79	1,253	33.31
80–89	547	14.54
≥90	42	1.12
Unknown or not recorded	5	0.13
Complication (yes/no)
No	51	1.36
Yes	3,704	98.46
Unknown or not recorded	7	0.19
Complication (by disease) (yes/no)
Hypertension
No	794	21.11
Yes	2,961	78.71
Unknown or not recorded	7	0.19
Hyperphosphatemia
No	1,604	42.64
Yes	2,151	57.18
Unknown or not recorded	7	0.19
Diabetes mellitus
No	1,993	52.98
Yes	1,762	46.84
Unknown or not recorded	7	0.19
Anemia
No	2,541	67.54
Yes	1,214	32.27
Unknown or not recorded	7	0.19
Hyperparathyroidism secondary
No	2,477	65.84
Yes	1,278	33.97
Unknown or not recorded	7	0.19
Duration of hemodialysis (years)
≤1	883	23.47
>1 to ≤2	490	13.02
>2 to ≤5	912	24.24
>5 to ≤10	777	20.65
>10	696	18.50
Unknown or not recorded	4	0.11
Allergy or hypersensitivity (yes/no)
No	2,800	74.43
Yes	633	16.83
Unknown or not recorded	329	8.75

Table 2

Summary of the treatment

Baseline treatment	Patients (n)	Ratio (%)
Registered department
Outpatient	2,824	75.07
Inpatient	182	4.84
Both out- and inpatient	755	20.07
Unknown or not recorded	1	0.03
Mean daily dose of nalfurafine (µg)
2.5	3,287	87.37
>2.5 to <5	436	11.59
5.0	28	0.74
>5.0	0	0.00
Unknown or not recorded	11	0.29
Total dose of nalfurafine (µg)
≤105	559	14.86
>105 to ≤210	247	6.57
>210 to ≤420	424	11.27
>420 to ≤840	380	10.10
>840	2,133	56.70
Unknown or not recorded	19	0.51
Treatment duration (number of days nalfurafine was given)
≤42	564	14.99
>42 to ≤84	256	6.80
>84 to ≤168	430	11.43
>168 to ≤365	518	13.77
>365	1,977	52.55
Unknown or not recorded	17	0.45
Frequency of dialysis (n/week)
<2	22	0.58
2	82	2.18
>2 to <3	95	2.53
3	3,546	94.26
>3 to <4	6	0.16
4	5	0.13
>4	0	0.00
Unknown or not recorded	6	0.16
Duration of dialysis (hours)
≤3	434	11.54
>3 to ≤4	2,928	77.83
>4 to ≤5	368	9.78
>5	23	0.61
Unknown or not recorded	9	0.24
Time to dialysis after nalfurafine administration (hours)
≤4	94	2.50
>4 to ≤8	39	1.04
>8 to ≤12	972	25.84
>12 to ≤16	1,779	47.29
>16 to ≤20	723	19.22
>20 to ≤24	125	3.32
>24	1	0.03
Unknown or not recorded	29	0.77
Previous treatment against pruritus (yes/no)
No	684	18.18
Yes	3,067	81.53
Unknown or not recorded	11	0.29
Concomitant treatment against pruritus (yes/no)
No	790	21.00
Yes	2,965	78.81
Unknown or not recorded	7	0.19
Concomitant treatment (yes/no)
No	87	2.31
Yes	3,675	97.69
Unknown or not recorded	0	0.00

Safety

Frequency of ADRs

The frequency of all ADRs is shown in Tables 3–6. Among the 3,762 patients analyzed for safety, 402 (10.69%) patients experienced 598 incidents of ADRs. The ADRs most commonly experienced were: insomnia, constipation, somnolence, dizziness, nausea, and malaise (Tables 3–6). The ADR found among the nine patients excluded from the safety analysis was one case of pruritus. Two or more incidents of serious ADRs included cerebral infarction in six patients (0.16%), hallucinations, Alzheimer’s type dementia, and abnormal hepatic function in three patients each (0.08%), and pneumonia, gastric cancer, anemia, hyperkalemia, insomnia, dizziness, acute myocardial infarction, myocardial infarction, peripheral arterial occlusive disease, pneumonia aspiration, pulmonary edema, ileus paralytic, death, and sudden death in two patients each (0.05%).

Table 3

List of ADRs for infections and infestations, neoplasms benign, malignant, and unspecified (including cysts and polyps), blood and lymphatic system disorders, endocrine disorders, metabolism and nutrition disorders.

Summary of ADR	Number or ratio
Number of study sites	1,002
Number of patients studied	3,762
Number of patients with ADRs	402
Number of ADR episodes	598
Ratio of patients with ADRs	10.69%
Types of ADRs	Number (%)
Infections and infestations	16 (0.43)
Appendicitis	1 (0.03)
Bronchitis	5 (0.13)
Fungal infection	1 (0.03)
Gastroenteritis	1 (0.03)
Herpes zoster	2 (0.05)
Meningitis bacterial	1 (0.03)
Nasopharyngitis	2 (0.05)
Peritonitis	1 (0.03)
Pneumonia	2 (0.05)
Subcutaneous abscess	1 (0.03)
Psoas abscess	1 (0.03)
Intervertebral discitis	1 (0.03)
Neoplasms benign, malignant, and unspecified (including cysts and polyps)	6 (0.16)
Colon cancer	1 (0.03)
Gastric cancer	2 (0.05)
Metastases to lymph nodes	1 (0.03)
Esophageal carcinoma	1 (0.03)
Uterine cancer	1 (0.03)
Lung neoplasm malignant	1 (0.03)
Blood and lymphatic system disorders	12 (0.32)
Anemia	3 (0.08)
Eosinophilia	1 (0.03)
Iron deficiency anemia	5 (0.13)
Nephrogenic anemia	4 (0.11)
Endocrine disorders	9 (0.24)
Basedow’s disease	1 (0.03)
Hyperparathyroidism secondary	2 (0.05)
Hyperprolactinemia	5 (0.13)
Hyperthyroidism	1 (0.03)
Thyrotoxic crisis	1 (0.03)
Metabolism and nutrition disorders	23 (0.61)
Dehydration	1 (0.03)
Diabetes mellitus	3 (0.08)
Hyperammonemia	1 (0.03)
Hypercalcemia	1 (0.03)
Hyperkalemia	2 (0.05)
Hyperphagia	1 (0.03)
Hyperphosphatemia	7 (0.19)
Hypertriglyceridemia	1 (0.03)
Hyperuricemia	1 (0.03)
Hypocalcemia	1 (0.03)
Hypokalemia	1 (0.03)
Polydipsia	1 (0.03)
Lipid metabolism disorder	1 (0.03)
Malnutrition	1 (0.03)
Decreased appetite	4 (0.11)
Hyperlipidemia	1 (0.03)

Notes: ADRs are coded with the preferred terms of MedDRA/J (version 18.1). The figure beside each category of disease shows the number (%) of patients with the type of ADR, while the number of each ADR shows the number of incidents (in parentheses, the number of incidents over the total number of patients researched).

Abbreviation: ADRs, adverse drug reactions.

Table 4

List of ADRs for psychiatric disorders, nervous system disorders, eye disorders, ear and labyrinth disorders, cardiac disorders, vascular disorders.

Types of ADRs	Number (%)
Psychiatric disorders	149 (3.96)
Anger	1 (0.03)
Anxiety	1 (0.03)
Completed suicide	1 (0.03)
Delirium	5 (0.13)
Depression	4 (0.11)
Hallucination	7 (0.19)
Hallucination, auditory	1 (0.03)
Hallucination, visual	1 (0.03)
Initial insomnia	1 (0.03)
Insomnia	127 (3.38)
Irritability	4 (0.11)
Listless	1 (0.03)
Logorrhea	1 (0.03)
Middle insomnia	1 (0.03)
Restlessness	5 (0.13)
Anxiety disorder	1 (0.03)
Nervous system disorders	91 (2.42)
Altered state of consciousness	2 (0.05)
Amnesia	1 (0.03)
Cerebral hemorrhage	1 (0.03)
Cerebral infarction	6 (0.16)
Cerebral thrombosis	1 (0.03)
Dementia	2 (0.05)
Dementia Alzheimer’s type	3 (0.08)
Dizziness	23 (0.61)
Dizziness postural	1 (0.03)
Dysarthria	2 (0.05)
Dysgeusia	2 (0.05)
Dyskinesia	1 (0.03)
Headache	3 (0.08)
Hypoesthesia	3 (0.08)
Memory impairment	1 (0.03)
Neuralgia	1 (0.03)
Neuropathy peripheral	2 (0.05)
Somnolence	32 (0.85)
Syncope	1 (0.03)
Tremor	2 (0.05)
Cognitive disorder	1 (0.03)
Restless legs syndrome	6 (0.16)
Thalamus hemorrhage	1 (0.03)
Hypoglycemic unconsciousness	1 (0.03)
Eye disorders	6 (0.16)
Blepharitis	1 (0.03)
Cataract	2 (0.05)
Conjunctivitis allergic	1 (0.03)
Diplopia	1 (0.03)
Eyelid edema	1 (0.03)
Ear and labyrinth disorders	6 (0.16)
Tinnitus	2 (0.05)
Vertigo	3 (0.08)
Sudden hearing loss	1 (0.03)
Cardiac disorders	17 (0.45)
Acute myocardial infarction	2 (0.05)
Angina pectoris	2 (0.05)
Arrhythmia	1 (0.03)
Atrial flutter	1 (0.03)
Cardiac failure	1 (0.03)
Cardiac failure acute	1 (0.03)
Cardiac failure congestive	1 (0.03)
Cardiorespiratory arrest	1 (0.03)
Myocardial infarction	2 (0.05)
Palpitations	4 (0.11)
Prinzmetal angina	1 (0.03)
Vascular disorders	7 (0.19)
Hypertension	4 (0.11)
Orthostatic hypotension	1 (0.03)
Peripheral arterial occlusive disease	2 (0.05)

Notes: ADRs are coded with the preferred terms of MedDRA/J (version 18.1). The figure beside each category of disease shows the number (%) of patients with the type of ADR, while the number of each ADR shows the number of incidents (in parentheses, the number of incidents over the total number of patients researched).

Abbreviation: ADRs, adverse drug reactions.

Table 5

List of ADRs for respiratory, thoracic, and mediastinal disorders, gastrointestinal disorders, hepatobiliary disorders, skin and subcutaneous tissue disorders, musculoskeletal and connective tissue disorders, reproductive system and breast disorders.

Types of ADRs	Number (%)
Respiratory, thoracic, and mediastinal disorders	12 (0.32)
Asthma	1 (0.03)
Bronchitis chronic	1 (0.03)
Cough	1 (0.03)
Hemoptysis	1 (0.03)
Interstitial lung disease	1 (0.03)
Pleurisy	1 (0.03)
Pneumonia aspiration	2 (0.05)
Pulmonary edema	2 (0.05)
Upper respiratory tract inflammation	2 (0.05)
Laryngeal discomfort	1 (0.03)
Gastrointestinal disorders	75 (1.99)
Abdominal discomfort	6 (0.16)
Abdominal distension	1 (0.03)
Abdominal pain	2 (0.05)
Chronic gastritis	2 (0.05)
Constipation	34 (0.90)
Diarrhea	5 (0.13)
Dyspepsia	1 (0.03)
Dysphagia	1 (0.03)
Enterocolitis	1 (0.03)
Gastric ulcer hemorrhage	1 (0.03)
Gastritis	3 (0.08)
Gastroesophageal reflux disease	3 (0.08)
Ileus paralytic	2 (0.05)
Intestinal obstruction	1 (0.03)
Irritable bowel syndrome	1 (0.03)
Lip swelling	1 (0.03)
Melena	1 (0.03)
Nausea	13 (0.35)
Esophageal varices hemorrhage	1 (0.03)
Pancreatitis acute	1 (0.03)
Stomatitis	2 (0.05)
Stress ulcer	1 (0.03)
Vomiting	5 (0.13)
Anal inflammation	1 (0.03)
Large intestine polyp	1 (0.03)
Hepatobiliary disorders	6 (0.16)
Cholecystitis acute	1 (0.03)
Hepatic function abnormal	4 (0.11)
Liver disorder	1 (0.03)
Skin and subcutaneous tissue disorders	19 (0.51)
Dermatitis contact	1 (0.03)
Dermatitis exfoliative	1 (0.03)
Drug eruption	1 (0.03)
Erythema	1 (0.03)
Papule	1 (0.03)
Pemphigoid	1 (0.03)
Pruritus	4 (0.11)
Rash	7 (0.19)
Skin exfoliation	2 (0.05)
Hangnail	1 (0.03)
Musculoskeletal and connective tissue disorders	9 (0.24)
Arthralgia	2 (0.05)
Back pain	4 (0.11)
Groin pain	1 (0.03)
Joint swelling	1 (0.03)
Muscle spasms	1 (0.03)
Musculoskeletal pain	3 (0.08)
Neck pain	1 (0.03)
Pain in extremity	1 (0.03)
Periarthritis	1 (0.03)
Spinal column stenosis	1 (0.03)
Reproductive system and breast disorders	5 (0.13)
Gynecomastia	4 (0.11)
Metrorrhagia	1 (0.03)

Notes: ADRs are coded with the preferred terms of MedDRA/J (version 18.1). The figure beside each category of disease shows the number (%) of patients with the type of ADR, while the number of each ADR shows the number of incidents (in parentheses, the number of incidents over the total number of patients researched).

Abbreviation: ADRs, adverse drug reactions.

Table 6

List of ADRs for general disorders and administration site conditions, investigations, injury, poisoning, and procedural complications.

Types of ADRs	Number (%)
General disorders and administration site conditions	26 (0.69)
Asthenia	2 (0.05)
Chest pain	1 (0.03)
Death	2 (0.05)
Feeling abnormal	4 (0.11)
Gait disturbance	1 (0.03)
Malaise	9 (0.24)
Multiorgan failure	1 (0.03)
Sudden death	2 (0.05)
Thirst	4 (0.11)
Investigations	21 (0.56)
Alanine aminotransferase increased	3 (0.08)
Aspartate aminotransferase increased	3 (0.08)
Blood lactate dehydrogenase increased	1 (0.03)
Blood parathyroid hormone increased	1 (0.03)
Blood prolactin increased	2 (0.05)
Blood triglycerides increased	1 (0.03)
Electrocardiogram T-wave amplitude decreased	1 (0.03)
Eosinophil count increased	1 (0.03)
Gamma-glutamyltransferase increased	5 (0.13)
Hemoglobin decreased	2 (0.05)
Liver function test abnormal	2 (0.05)
Platelet count decreased	1 (0.03)
White blood cell count decreased	1 (0.03)
Zinc sulfate turbidity increased	1 (0.03)
Bone density decreased	1 (0.03)
Blood phosphorus increased	1 (0.03)
Thymol turbidity test increased	1 (0.03)
Triiodothyronine free decreased	1 (0.03)
Thyroxine free increased	1 (0.03)
Blood alkaline phosphatase increased	4 (0.11)
Injury, poisoning, and procedural complications	11 (0.29)
Ankle fracture	1 (0.03)
Fall	1 (0.03)
Femur fracture	1 (0.03)
Head injury	1 (0.03)
Shunt occlusion	1 (0.03)
Spinal compression fracture	2 (0.05)
Subdural hematoma	1 (0.03)
Brain contusion	1 (0.03)
Shunt malfunction	1 (0.03)
Procedural hypotension	3 (0.08)

Notes: ADRs are coded with the preferred terms of MedDRA/J (version 18.1). The figure beside each category of disease shows the number (%) of patients with the type of ADR, while the number of each ADR shows the number of incidents (in parentheses, the number of incidents over the total number of patients researched).

Abbreviation: ADRs, adverse drug reactions.

Frequency of sleep disorder and other psychiatric disorders

The sleep disorders experienced included insomnia (127 [3.38%]), somnolence (32 [0.85%]), and one case (0.03%) each of initial insomnia and middle insomnia. The identified psychiatric disorders included 127 (3.38%) cases of insomnia, 7 (0.19%) cases of hallucination, 5 (0.13%) each of delirium and restlessness, and 4 (0.11%) each of depression and irritability (Table 4).

Coadministration of hypnotic, antianxiety, antidepressant, antipsychotic, or antiepilepsy drugs

The number of ADRs was counted for each of the three categories of concomitant drugs (Table 7). Antidepressants are included in the residual category of “other antipsychotic drugs”. There was no major difference among the categories for the most frequent insomnia.

Table 7

Safety of combination therapies with hypnotic, antianxiety, antidepressant, antipsychotic, or antiepilepsy drugs

Types of ADRs	Number (%) of patients analyzed for safety	Hypnotic/antianxiety	Antiepileptic drugs	Other antipsychotic drugs
Number of patients studied	3,762	1,029	130	482
Number (%) of patients with ADRs by the type of ADRs
Psychiatric disorders	149 (3.96)	45 (4.37)	5 (3.85)	33 (6.85)
Anger	1 (0.03)	1 (0.10)	0 (0.00)	1 (0.21)
Anxiety	1 (0.03)	0 (0.00)	0 (0.00)	0 (0.00)
Completed suicide	1 (0.03)	0 (0.00)	0 (0.00)	0 (0.00)
Delirium	5 (0.13)	1 (0.10)	1 (0.77)	3 (0.62)
Depression	4 (0.11)	2 (0.19)	0 (0.00)	2 (0.41)
Hallucination	7 (0.19)	2 (0.19)	0 (0.00)	1 (0.21)
Hallucination, auditory	1 (0.03)	1 (0.10)	0 (0.00)	1 (0.21)
Hallucination, visual	1 (0.03)	0 (0.00)	0 (0.00)	0 (0.00)
Initial insomnia	1 (0.03)	0 (0.00)	0 (0.00)	0 (0.00)
Insomnia	127 (3.38)	40 (3.89)	4 (3.08)	24 (4.98)
Irritability	4 (0.11)	1 (0.10)	0 (0.00)	1 (0.21)
Listless	1 (0.03)	0 (0.00)	0 (0.00)	0 (0.00)
Logorrhea	1 (0.03)	1 (0.10)	0 (0.00)	0 (0.00)
Middle insomnia	1 (0.03)	0 (0.00)	0 (0.00)	0 (0.00)
Restlessness	5 (0.13)	2 (0.19)	0 (0.00)	2 (0.41)
Anxiety disorder	1 (0.03)	0 (0.00)	0 (0.00)	0 (0.00)
Nervous system disorders	91 (2.42)	34 (3.30)	3 (2.31)	15 (3.11)
Altered state of consciousness	2 (0.05)	1 (0.10)	0 (0.00)	1 (0.21)
Amnesia	1 (0.03)	1 (0.10)	0 (0.00)	0 (0.00)
Cerebral hemorrhage	1 (0.03)	0 (0.00)	0 (0.00)	0 (0.00)
Cerebral infarction	6 (0.16)	3 (0.29)	0 (0.00)	1 (0.21)
Cerebral thrombosis	1 (0.03)	0 (0.00)	0 (0.00)	0 (0.00)
Dementia	2 (0.05)	2 (0.19)	1 (0.77)	0 (0.00)
Dementia Alzheimer’s type	3 (0.08)	0 (0.00)	0 (0.00)	1 (0.21)
Dizziness	23 (0.61)	7 (0.68)	0 (0.00)	3 (0.62)
Dizziness postural	1 (0.03)	0 (0.00)	0 (0.00)	0 (0.00)
Dysarthria	2 (0.05)	1 (0.10)	0 (0.00)	0 (0.00)
Dysgeusia	2 (0.05)	2 (0.19)	1 (0.77)	0 (0.00)
Dyskinesia	1 (0.03)	0 (0.00)	0 (0.00)	1 (0.21)
Headache	3 (0.08)	1 (0.10)	0 (0.00)	0 (0.00)
Hypoesthesia	3 (0.08)	1 (0.10)	0 (0.00)	0 (0.00)
Memory impairment	1 (0.03)	1 (0.10)	0 (0.00)	0 (0.00)
Neuralgia	1 (0.03)	1 (0.10)	0 (0.00)	0 (0.00)
Neuropathy peripheral	2 (0.05)	1 (0.10)	0 (0.00)	1 (0.21)
Somnolence	32 (0.85)	9 (0.87)	0 (0.00)	5 (1.04)
Syncope	1 (0.03)	1 (0.10)	0 (0.00)	1 (0.21)
Tremor	2 (0.05)	2 (0.19)	0 (0.00)	1 (0.21)
Cognitive disorder	1 (0.03)	0 (0.00)	0 (0.00)	0 (0.00)
Restless legs syndrome	6 (0.16)	3 (0.29)	1 (0.77)	2 (0.41)
Thalamus hemorrhage	1 (0.03)	1 (0.10)	0 (0.00)	0 (0.00)
Hypoglycemic unconsciousness	1 (0.03)	0 (0.00)	0 (0.00)	0 (0.00)

Notes: ADRs are coded with the preferred terms of MedDRA/J (version 18.1). The figure beside each category of disease shows the number (%) of patients with the type of ADR, while the number of each ADR shows the number of incidents (in parentheses, the number of incidents over the total number of patients researched).

Abbreviation: ADRs, adverse drug reactions.

Changes in serum prolactin and thyroid hormones

Measurements were obtained before and after the onset of nalfurafine treatment. A statistically significant decrease of serum TSH was observed, with the pretreatment level being 2.39±2.37 to 2.00±1.90 μIU/mL after the initiation of nalfurafine treatment (p=0.035; Table 8). Although two adverse events in two patients of lower TSH levels were observed, causal relationships between the adverse events and nalfurafine were rejected.

Table 8

Assessment of serum prolactin and thyroid hormones before and after the treatment onset

Test item (unit)	Patients (n)	Assessment timing	Mean	SD	Min	Median	Max	One-sample t-test
Prolactin (ng/mL)	53	1 month or shorter before the initial dose	47.04	147.95	4.00	18.90	1,083.79	p=0.323
		After the initial dose (latest measurement)	59.14	231.74	5.23	19.40	1,705.57
		Change from the pretreatment measurement	12.10	88.22	−135.77	0.90	621.78
TSH (μIU/mL)	132	1 month or shorter before the initial dose	2.39	2.37	0.00	1.70	13.80	p=0.035*
		After the initial dose (latest measurement)	2.00	1.90	0.00	1.63	11.30
		Change from the pretreatment measurement	−0.39	2.12	−12.00	−0.01	6.07
FT3 (pg/mL)	104	1 month or shorter before the initial dose	2.13	0.49	0.70	2.15	4.12	p=0.513
		After the initial dose (latest measurement)	2.10	0.59	0.80	2.00	4.80
		Change from the pretreatment measurement	−0.03	0.41	−1.00	0.00	2.30
FT4 (ng/dL)	124	1 month or shorter before the initial dose	1.01	0.25	0.58	1.00	2.07	p=0.505
		After the initial dose (latest measurement)	1.02	0.25	0.53	1.00	1.93
		Change from the pretreatment measurement	0.01	0.19	−0.41	0.00	0.88

Notes: The difference between the measurements at 1 month or shorter before the initial dose and the latest measurement after the initial dose.

p<0.05; significance was tested by one-sample t-test.

Abbreviations: FT3, free triiodothyronine; FT4, free thyroxine; max, maximum; min, minimum; TSH, thyroid-stimulating hormone.

Dependence

We collected 3,265 “on-treatment” responses and 530 “off-treatment” responses on evaluating the first 12 weeks, and 2,324 “on-treatment” responses and 257 “off-treatment” responses on evaluating the period from 13 weeks to 1 year. None of the nine patients excluded from the safety analysis were assigned as “remarkable” or “moderate” to any of the questions. “Remarkable” or “moderate” evaluations were most often obtained for three “on-treatment” questions (ie, “Do you want to continue taking this drug?”; “Do you think this drug became less effective?”; “Do you want to take this drug in a larger dosis?”), as shown in Tables 9 and 10. Dependence was further examined by analyzing the patients’ own explanations and the physicians’ findings that accompanied “remarkable” or “moderate” responses, in cases where such concurring feedback was frequent for particular question items. First, of the patients in the category of “remarkable” or “moderate” for the psychological dependence-related question “Do you want to continue taking this drug?”, as many as 434 in the first 12 weeks and 252 from 13 weeks to 1 year mentioned reasons such as “withdrawal from the agent may aggravate pruritus”, simply anticipating symptom relief associated with use of the agent. Likewise, none of the remainder who were all rated “moderate” for the same question item had any reasons or expert observations that suggested dependence. All patients answering “remarkable” or “moderate” for the psychological dependence-related question “Do you want to take this drug in a larger dosis?” expressed hope for greater efficacy. None of the “remarkable” or “moderate” responses to any other question items were accompanied by reasons or expert findings that suggested psychological dependence. Then, very few patients were assigned as being “remarkable” or “moderate” for the physical dependence-related questions. Finally, while some of the patients who responded “remarkable” or “moderate” to the tolerance-related question “Do you think this drug became less effective?” (in the first 12 weeks: 40 patients; from 13 weeks to 1 year: 26 patients) were evaluated to be showing “weaker efficacy”, no reasons or physician findings suggesting the dependence were given.

Table 9

Summary of results of dependence (psychological dependence, physical dependence, tolerance) assessment (up to 12 weeks)

Assessment timing	Questions	Patients (n)	Remarkable	Moderate	Slight	None	Unknown	Remarkable or moderate	Slight or none
On-treatment (12 weeks after the initial dose)	Do you feel clearheaded on this drug?	3,252	0	3	84	3,164	1	3	3,248
	Do you feel indifferent to disliked persons or things on this drug?	3,262	1	6	62	3,192	1	7	3,254
	Do you become hyperactive or talkative on this drug?	3,261	1	3	45	3,211	1	4	3,256
	Do you become broad-minded on this drug?	3,262	0	3	37	3,221	1	3	3,258
	Do you feel intoxicated on this drug?	3,261	2	3	75	3,180	1	5	3,255
	Do you feel irritable or somewhat lonely when the drug effect runs out?	3,260	1	3	51	3,204	1	4	3,255
	Do you want to continue taking this drug?	3,261	119	317	708	2,115	2	436	2,823
	Do you think this drug became less effective?	3,260	6	34	280	2,938	2	40	3,218
	Do you want to take this drug in larger doses?	3,261	2	26	191	3,042	0	28	3,233
	Do you feel nauseated or tremulous when the drug effect runs out?	3,261	1	0	25	3,235	0	1	3,260
Off-treatment (4 weeks after the end [or interruption] of the treatment)	Have you felt irritable or unstable after you were off this drug?	530	2	0	3	525	0	2	528
	Have you had more difficulty in sleeping after you were off this drug?	530	2	1	8	519	0	3	527
	Have you had nausea, vomiting, tremors of limb, or perspiration after you were off this drug?	530	0	0	3	527	0	0	530
	Do you really want to take this drug again?	530	1	4	39	486	0	5	525
	Have you had convulsions after you were off this drug?	530	0	0	0	530	0	0	530
	Have you had clouded mind or heard or seen anything unusual after you were off this drug?	530	0	0	1	529	0	0	530

Table 10

Summary of results of dependence (psychological dependence, physical dependence, tolerance) assessment (13 weeks–1 year)

Assessment timing	Questions	Patients (n)	Remarkable	Moderate	Slight	None	Unknown	Remarkable or moderate	Slight or none
On-treatment (1 year after the initial dose)	Do you feel clearheaded on this drug?	2,306	0	1	41	2,264	0	1	2,305
	Do you feel indifferent to disliked persons or things on this drug?	2,317	1	5	24	2,287	0	6	2,311
	Do you become hyperactive or talkative on this drug?	2,317	0	2	20	2,295	0	2	2,315
	Do you become broad-minded on this drug?	2,317	0	1	18	2,298	0	1	2,316
	Do you feel intoxicated on this drug?	2,317	1	1	25	2,290	0	2	2,315
	Do you feel irritable or somewhat lonely when the drug effect runs out?	2,318	0	1	34	2,283	0	1	2,317
	Do you want to continue taking this drug?	2,318	82	171	508	1,557	0	253	2,065
	Do you think this drug became less effective?	2,317	5	21	166	2,125	0	26	2,291
	Do you want to take this drug in larger doses?	2,317	3	5	85	2,224	0	8	2,309
	Do you feel nauseated or tremulous when the drug effect runs out?	2,317	0	0	9	2,308	0	0	2,317
Off-treatment (4 weeks after the end [or interruption] of the treatment)	Have you felt irritable or unstable after you were off this drug?	257	0	0	3	254	0	0	257
	Have you had more difficulty in sleeping after you were off this drug?	257	0	1	2	254	0	1	256
	Have you had nausea, vomiting, tremors of limb or perspiration after you were off this drug?	256	0	0	0	256	0	0	256
	Do you really want to take this drug again?	257	0	6	18	233	0	6	251
	Have you had convulsions after you were off this drug?	257	0	0	0	257	0	0	257
	Have you had clouded mind or heard or seen anything unusual after you were off this drug?	257	0	0	1	256	0	0	257

Efficacy

Global assessment of the itch improvement

At 12 weeks, 3,491 patients were analyzed, excluding 269 whose data were indeterminate or unknown. At 1 year, 2,551 patients were analyzed, while 1,021 who discontinued until 12 weeks and 188 whose data were indeterminate or unknown were excluded from the analysis (Figure 1). Nalfurafine was determined to be effective (ie, as evidenced by improvement in itch severity) in 82.50% (2,880/3,491 patients) of patients at 12 weeks and 84.95% (2,167/2,551 patients) of patients at 1 year.

Visual Analog Scale

At 12 weeks, 835 patients were analyzed, excluding 2,925 who had incomplete data. At 1 year, 571 patients were analyzed, while 1,021 who discontinued until 12 weeks and 2,168 who had incomplete data were excluded from the analysis (Figure 1). The VAS value decreased significantly from the pretreatment level of 75.8±19.2 to 38.6±26.5 mm at 12 weeks (p<0.001). Furthermore, the 34.3±26.0 mm VAS value at 1 year was also lower than the baseline level of 76.6±19.1 mm; the decrease was statistically significant (p<0.001; Figure 2).

Figure 2

VAS values (mm) scores before and after the treatment onset.

Note: *p<0.001; significance was tested by one-sample t-test of the posttreatment figures against the pretreatment figures.

Abbreviations: max, maximum; min, minimum; VAS, Visual Analog Scale.

Shiratori’s severity score

At 12 weeks, 1,195 patients among the efficacy analysis population were analyzed, excluding 2,565 who had incomplete data. At 1 year, 804 patients among the efficacy analysis population were analyzed, excluding 1,021 who discontinued until 12 weeks and 1,935 who had incomplete data (Figure 1). The decrease in the Shiratori’s severity score from the pretreatment level of 3.3±0.6 to 1.8±1.0 at 12 weeks was statistically significant (p<0.001). The score of 1.6±1.0 at 1 year was also significantly lower than the pretreatment value of 3.3±0.6 (p<0.001; Figure 3).

Figure 3

Shiratori’s severity scores before and after the treatment onset.

Note: *p<0.001; significance was tested by one-sample t-test of the posttreatment figures against the pretreatment figures.

Abbreviations: max, maximum; min, minimum.

Discussion

This present PMS analyzed the safety and efficacy of nalfurafine in hemodialysis patients with intractable pruritus. As some items included in this surveillance are not required prerequisites for regulatory PMS, data could not be obtained unless the specific items were routinely measured by physicians at a participating institution. Consequently, a considerable number of cases with incomplete data had to be excluded from the efficacy analysis, which included strictly those patients whose evaluation was available twice daily, both before and after administration of nalfurafine. It may be argued that such exclusion has resulted in a biased body of patients. However, it is noteworthy that the number of patients was sufficiently large to conduct the safety analysis, which is an important consideration given that the primary purposes of this surveillance were to reevaluate known risks in actual clinical settings and detect any new or hidden safety risks.

The recommended dose of nalfurafine for adults is 2.5 μg once daily, administered orally after an evening meal or before bedtime. The dose can be increased in accordance with the symptoms; the maximum dose is 5.0 μg once daily. The frequency of ADRs in the elevation-to-5.0 μg group was 9.68% (42/434 patients); the frequency was 10.92% (359/3,287 patients) in the 2.5 μg group. Global assessment of the itch improvement showed improvement at 1 year in 86.08% (186/2,162) and 78.77% (282/358) of patients among the regular 2.5 μg dose and the elevation-to-5.0 μg group patients, respectively. Increasing the dose from 2.5 to 5.0 μg was because of more severe pruritus and/or due to insufficient efficacy. Despite supposedly more severe baseline disease of the elevation-to-5.0 μg group, symptom improvement was evident in nearly 80% of patients with similar rate of ADRs. Dose elevation occurred more frequently during the period between 2 and 4 weeks after nalfurafine treatment onset than any other period. Some institutions are reported to switch to 5.0 μg nalfurafine if 2.5 μg dose does not prove to be sufficiently effective after a 2–4-week observation period.32 Therefore, it seems a reasonable strategy to schedule an assessment after a set period of time since initiation of treatment with nalfurafine 2.5 μg, so that the dose may be elevated to 5.0 μg if required.

Those patients who have a shorter history of hemodialysis are anticipated to be in a less stable clinical condition. In this surveillance, 23.47% (883/3,762) of patients had a history of 1 year or shorter. ADRs were experienced by 9.17% (81/883) of these “novice” patients; an improved level of itch by global assessment at 1 year was achieved by 87.09% (553/635) of this population. However, no difference in these safety and efficacy levels was noted among the patients of hemodialysis induction of <1 year and the patients of hemodialysis induction of 1 year or more. Therefore, nalfurafine is demonstrated to be safe and effective in early-stage hemodialysis patients.

The ADR incidence of 10.69% (402/3,762 patients) in this surveillance was lower than the incidences of 25.0% (28/112 patients, 2.5 μg arm), 35.1% (40/114 patients, 5 μg arm) in the placebo-controlled, double-blind study, or 48.8% (103/211 patients, 5 μg arm) in the long-term study.26,27 The type of most frequently experienced ADRs was the same as previous studies, and the incidence of these ADRs was essentially no different from those noted in previous studies. We also investigated the onset timing of the three most frequently experienced ADRs (ie, insomnia, constipation, and somnolence). Insomnia was experienced within 3 days by 26.77% (34/127 patients) and within 2 weeks by 55.90% (71/127 patients). Constipation began within 3 days in 20.58% (7/34 patients) and within 2 weeks in 44.12% (15/34 patients). The onset of somnolence was noted within 3 days in 21.88% (7/32 patients) and within 2 weeks in 56.25% (18/32 patients). It, therefore, seems that the common ADRs of nalfurafine may set in at a relatively early stage of treatment.

When we examined the frequency of sleep disorders and psychiatric disorders among the ADRs in comparison with the frequency of such ADRs in preceding clinical trials for hemodialysis patients, no significant difference or noteworthy issues were found. The only ADR with a ≥3% frequency was insomnia (3.38%). Its frequency was lower than that of 7.1% (8/112 patients, 2.5 μg arm), 14.0% (16/114 patients, 5 μg arm) in the placebo-controlled, double-blind study, or 19.4% (41/211 patients, 5 μg arm) in the long-term study.26,27 This surveillance found no previously unknown hidden risks related to sleep disorders or psychiatric disorders.

The frequencies of psychiatric disorders and nervous system disorders associated with nalfurafine coadministration with central nervous system agent were both lower than the values found in preceding domestic clinical trials for hemodialysis patients, namely, 16.42% (100/609, at approval) for psychiatric disorders and 6.73% (41/609, at approval) for nervous system disorders. A relatively higher frequency of psychiatric disorders was found in patients who used “other antipsychotic drugs”, but the number of patients who experienced each specific type of ADRs, excluding insomnia, was not more than three. Insomnia was the most common ADR associated with coadministration (4.98% [24/482] of patients). However, the frequency was lower than that observed in the preceding domestic clinical trials for hemodialysis patients at 15.27% (93/609, at approval). This surveillance found no previously unknown latent risks related to psychiatric disorders or nervous system disorders.

Preceding clinical trials had noted one patient who experienced temporary gynecomastia. This surveillance also found four patients with gynecomastia, urging sufficient attention to increased levels of serum prolactin. We noticed a few types of ADRs that could possibly manifest a lower TSH level. Three incidents in two patients of Graves’ disease, hyperthyroidism, and thyrotoxic crisis (one each) were reported, but they could not be included in the analysis comparing the pre- and posttreatment levels because their serum TSH levels had not been recorded. There was also one such adverse event whose association with nalfurafine administration had been rejected; one incident of goiter was reported in a patient, but the patient was excluded from the analysis because serum TSH level of the patient was not available. Therefore, while there appears to be no previously unknown or hidden risks in relation to serum prolactin, the investigation of nalfurafine’s potential effect on thyroid hormones can be considered to be insufficient. The effect of nalfurafine on the endocrine system had been confirmed in previous nonclinical and clinical trials. The agent appears to induce endocrinal changes by actions common to those of opioids, which are known to act on the central nervous system and may trigger endocrinal disorders.32 Therefore, tests as appropriate are recommended during administration of nalfurafine.

In this Questionnaire of Drug Dependence, none of the patients’ own explanations or physicians’ observations suggested possibilities of dependence (psychological dependence, physical dependence, or tolerance). Although this surveillance noted no previously unknown risks of developing dependence on the agent, long-term administration of the agent seems to increase the risk of a patient developing dependence. It is, therefore, important that we continue to collect clinical data related to dependence issues.

Efficacy was shown by the significantly decreased VAS values at both 12 weeks and 1 year. Since this surveillance lacks a placebo arm, comparison with previous clinical trials cannot be made. Efficacy assessment in the placebo-controlled, double-blind study was conducted by checking the VAS values before and 14 days after the initial dose of nalfurafine.26 The changes in VAS were 15.31 mm (n=111; 95% CI, 11.53–19.09), 24.45 mm (n=112; 95% CI, 20.68–28.21), and 23.44 mm (n=114; 95% CI, 19.78–27.11) in the placebo arm, nalfurafine 2.5 μg arm, and 5 μg arm, respectively. The long-term study found a VAS change of 43.88 mm (n=145; 95% CI, 39.60–48.16) between pretreatment and 52 weeks after nalfurafine treatment onset.27 The change of VAS in this surveillance is equivalent to those of above trials. Moreover, a similar tendency was found in the Shiratori’s severity score. The results of the global assessment of the itch improvement showed improvement both at 12 weeks and 1 year. In contrast to the VAS and the Shiratori’s severity score that reflected the patient’s subjective self-assessment, the global assessment of the itch improvement was determined by physicians evaluating the degree of patients’ pruritus. Interestingly, this surveillance demonstrated the itch-reducing efficacy of nalfurafine from the perspective of both patients and experts.

Limitations

This surveillance is a prospective observation based on predetermined survey items. It lacks a control arm. As such, interpretation of the survey results has certain limitations inherent in this standard approach. The limitation of this surveillance is that the number of the patients between safety analysis and efficacy analysis was very different. In particular, the number of patients whose prolactin was measured was very small. Furthermore, efficacy was not examined for each dose at 12 weeks and 1 year after treatment.

Conclusion

This surveillance found sufficient safety and efficacy of nalfurafine as an indication for improvement of intractable pruritus in hemodialysis patients. Regarding the safety profile of this agent, no previously unknown hidden risks were identified. In May 2015, nalfurafine was approved in Japan for the additional indication for improvement of pruritus in chronic liver disease patients (use only when sufficient efficacy is not obtained with existing therapies or treatments). Application for another indication, that is, improvement of pruritus in peritoneal dialysis patients, has been filed, and the approval process is ongoing. In order to promote the proper and appropriate use of nalfurafine, we will continue to accumulate further safety and efficacy data, including the incidents of ADRs.